Drugs and patents in ATC class L02BG

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
CYTADREN	aminoglutethimide
ANASTROZOLE	anastrozole
ARIMIDEX	anastrozole
FEMARA	letrozole
LETROZOLE	letrozole
KISQALI FEMARA CO-PACK (COPACKAGED)	letrozole; ribociclib succinate
AROMASIN	exemestane
>Tradename	>Generic Name

Last updated: June 22, 2026

Aromatase inhibitors (ATC L02BG) market dynamics and patent landscape for generics, biosimilars, and formulation shifts

ATC L02BG aromatase inhibitors are dominated by multiple, off-patent small-molecule brands (letrozole, anastrozole, exemestane) plus still-protected, newer delivery formats and indications in specific jurisdictions. The commercial center of gravity is largely price compression in the US and EU for legacy oral tablets, while patent value concentrates in: (1) method-of-treatment claims (especially early breast cancer schedules, extended adjuvant therapy, and line-of-therapy expansions); (2) pediatric-adaptation and dosing/regimen claims; (3) formulation patents tied to specific release characteristics and manufacturing processes; and (4) late-expiring jurisdiction-specific “secondary” patents that can delay generic entry via Paragraph IV or SPC term adjustments where available.

Key market dynamic: despite years of generic penetration, the basket remains commercially durable because aromatase inhibitors are standard-of-care across early and advanced hormone receptor positive breast cancer. That sustained demand supports brand shelf-life extensions through line-of-therapy differentiation, population-specific labeling, and “life-cycle” formulation or regimen patents.

Patent dynamic: most core API compositions are long expired. The remaining enforceable IP is typically “secondary” and jurisdiction-fragmented, with litigation risk concentrated where brand owners still hold enforceable formulation and method-of-use claims covering on-label regimens and dosing.

Which aromatase inhibitors are in ATC L02BG and how do their patents typically break down?

What drugs sit in ATC L02BG

ATC L02BG is the aromatase inhibitor class used in breast cancer endocrine therapy and includes:

Letrozole
Anastrozole
Exemestane (also spelled exemestane; marketed as exemestane in some regions)
Other aromatase inhibitors may appear depending on national ATC implementations, but the practical market and patent landscape are driven by the three above.

Patent estate pattern across the class

For all three major APIs, the typical estate structure is:

Original composition and process claims (expired or near-expired).
Crystallization/polymorph and solid-state form claims (can extend protection).
Formulation claims (tablet compositions, excipient sets, dissolution profiles).
Method-of-use claims (regimen duration, patient subgroups, switching/sequence vs tamoxifen, extended adjuvant therapy windows, and specific line-of-treatment in metastatic disease).
Pediatric investigation plan-related adaptations (where protections were granted).
Regulatory exclusivities and SPC/extension mechanisms in the EU for selected dossiers.

What patents protect letrozole, anastrozole, and exemestane in 2026 and where is enforceability most likely?

A complete, drug-by-drug “what patents protect what” map requires live Orange Book and jurisdiction-specific patent/SPC inventories. The operational takeaway for L02BG is that enforceability is concentrated in secondary patents rather than composition-of-matter.

Letrozole: where the remaining patent value usually sits

For letrozole, the remaining litigable value generally comes from:

Solid-state forms and crystal form/polymorph claims tied to manufacturability.
Specific tablet formulation claims that can be used to block “same-dose, same-API” generics if claim scope maps to excipient and dissolution targets.
Method-of-use claims tied to extended adjuvant regimens and sequence therapy.

Anastrozole: where remaining value usually sits

For anastrozole, residual enforceability typically covers:

Formulation and manufacturing (granulation, compression, dissolution profile).
Regimen/method-of-use expansions tied to early-stage duration and patient subsets.

Exemestane: where remaining value usually sits

For exemestane, residual enforceability tends to cluster around:

Solid-state and process patents, where ANDA generics must match not just active ingredient but also the claim-covered manufacturing and form.
Method-of-use tied to switch-therapy schedules and adjuvant extensions.

When does aromatase inhibitor patent exclusivity end, and what drives generic launch timing?

Featured snippet: what typically controls launch dates

Generic launch timing is controlled by:

Expiration of primary and secondary patents listed in US Orange Book (when present).
Last effective date of listed patents (35 USC 355(b) framework in practice).
EU SPC expiries and any national extension mechanisms.
Regulatory exclusivities (less common for well-established APIs, but still relevant for specific product configurations).
Litigation and settlements that trigger “180-day” exclusivity for Paragraph IV filers in the US.

Timing dynamics for secondary patents

Secondary patents can keep a brand commercially protected long after API expiration if they are:

Directly listed to cover the marketed dosage form strength(s), or
Found-infringement mapped to generic ANDA formulations that target bioequivalence.

Practical effect: even with extensive generic availability at the API level, brand owners can maintain premium pricing in certain strengths or package configurations where enforceable formulation or use claims still apply.

How many patents cover aromatase inhibitors on the Orange Book and how broad is the remaining claim scope?

Featured snippet: Orange Book coverage is typically “a long list, a small enforceable subset”

In mature API categories like L02BG, Orange Book listings often include multiple patents per product, but only a subset is:

enforceable at a given time,
mapped to a claim that reads onto generic formulation manufacturing and/or label use,
actively asserted or likely to be asserted.

Operationally, the defendable claim space tends to shrink over time. As a result, generic launch risk is driven by whether a specific ANDA product:

uses a formulation that falls within claim limitations, and
is designed to be substituted for brand label use under FDA labeling.

What generic entry risks exist for letrozole, anastrozole, and exemestane via Paragraph IV ANDAs?

Featured snippet: paragraph IV risk is formulation and method-of-use driven

For aromatase inhibitors, Paragraph IV challenges typically focus on:

Non-infringement of formulation composition and dissolution profile limitations.
Invalidity of secondary patents (novelty, obviousness, enablement, written description).
Lack of Orange Book listing linkage to the exact strength, dosage form, or labeled indication.

Where ANDA challengers typically face higher friction

Higher friction appears when:

the patent is a solid-state form or manufacturing process claim, making “design-around” harder;
the patent is tied to the marketed tablet rather than a generic “therapeutic equivalent” concept;
litigation history indicates a history of narrow design-around success.

What patent litigation affects aromatase inhibitors and how do settlements shape future generic timing?

Featured snippet: settlements often trade away the first entrant’s 180-day window

In the US, aromatase inhibitor generic entries can be accelerated or delayed based on:

Stipulated settlement dates (brand buys time, generic gets a scheduled entry).
Working agreements where generic agrees to delay launch beyond statutory minimums.
Consent judgments that convert disputed claims into predictable entry calendars.

For portfolio-level strategy, the business lever is the settlement pattern:

If a brand historically settles quickly, challengers can anticipate a predictable “entry on a date” rather than protracted injunction risk.
If a brand litigates aggressively on formulation or solid-state claims, generic challengers face higher injunction odds and broader discovery burdens.

What is the Orange Book status of aromatase inhibitors and which companies are most active?

Orange Book status: class-level reality

For L02BG, Orange Book status is usually:

Multiple generics on market for each major API.
Ongoing brand listings for secondary patents that may still be listed on at least one strength or product presentation.
Periodic “late” filings tied to formulation variants.

Company activity: how it typically clusters

Brand originators maintain listings and enforce secondary IP.
Large generic manufacturers file multiple ANDAs and settle where enforceability risk is manageable.
Specialty generics and formulation developers pursue design-arounds for specific strengths or dissolution targets.

(Company-by-company litigation and listing counts require current Orange Book pulls and court docket matching; a class-level analysis is therefore limited to the structural pattern.)

How do formulation patents on aromatase inhibitors affect bioequivalence, switching, and payer decisions?

Formulation patents are a business lever, not a bioequivalence lever

US ANDA approval is based on demonstrating bioequivalence. The IP lever comes from whether the generic formulation:

falls within a patent’s composition or manufacturing constraints, or
uses a solid-state form the patent protects.

Key formulation/IP friction points

Particle size and milling that impact dissolution.
Excipients that materially affect tablet matrix and dissolution rate.
Solid-state form selection (polymorph or crystal form) that changes process controls and potentially claim coverage.
Manufacturing process steps (granulation, compression force targets, drying conditions).

Payers rarely distinguish at the API level once generics are approved, but brand-to-generic substitution can still be slowed by:

pharmacy contract structures,
formulary management transitions,
temporary “at-risk” supply disruptions during litigation or design-around transitions.

How do method-of-use patents for aromatase inhibitors affect indication-specific generic substitution?

Featured snippet: method-of-use claims can block product use, not just product approval

Method-of-use patents can limit substitution where:

the generic’s label is carved to avoid infringing use claims, or
courts interpret infringement based on on-label practices.

Practical effect in endocrine therapy: even when a generic is approved, payer and prescriber behavior can remain brand-favored if label language or switching guidance remains cautious during litigation.

Method-of-use claim categories in this class often track:

adjuvant duration and switching protocols,
sequence therapy with tamoxifen,
extended adjuvant therapy beyond initial treatment windows,
metastatic line-of-therapy distinctions.

Which regions have the biggest residual legal barriers for generics of aromatase inhibitors?

Featured snippet: EU SPC and national patent calendars are the main geographic differentiators

Residual barriers vary by:

whether SPCs exist and whether they were extended,
national patent enforcement intensity,
whether courts interpret secondary patents broadly in formulation claims,
local litigation speed and injunction practices.

Operational pattern:

US timing is driven by Orange Book listings, ANDA Paragraph IV strategy, and settlement calendars.
EU timing is driven by SPC expiries, local patent validity outcomes, and cross-country enforcement.

How does the aromatase inhibitor patent landscape compare with other L02BG-adjacent endocrine therapies?

Aromatase inhibitors differ from some adjacent endocrine classes in that:

they are established oral small molecules with heavy generic penetration,
the remaining patent value tends to be in secondary patents rather than transformative platform innovation.

Compared with:

SERMs (tamoxifen class) where generics also predominate and lifecycle IP is common,
selective estrogen receptor degraders (SERDs) in later endocrine eras where biologic-like complexity shifts the IP focus toward biologics/manufacturing and molecular claims, L02BG’s enforceability is usually lower in novelty and higher in formulation and regimen survivability.

What is the commercial exposure from remaining exclusivity in aromatase inhibitors?

Featured snippet: exposure is now concentrated in fewer SKUs and fewer strengths

Even after years of generic entry, brand revenue can persist when:

generics enter “in waves” across strengths,
some presentation is held off by secondary patent coverage,
payer contracts keep brand on formulary longer than approvals alone would suggest.

Commercial diligence should focus on:

the specific strength and dosage form being marketed under the latest label,
any parallel product (reformulated tablet, different pack size, or patient-dosing convenience variants),
the time remaining on the most relevant formulation or method-of-use patent(s).

Key Takeaways

ATC L02BG aromatase inhibitors are commercially durable but structurally generic at the API level; the enforceable value concentrates in secondary patents: formulation, solid-state form, manufacturing, and method-of-use/regimen.
Generic launch timing is governed by Orange Book-listed patents (US), SPC and national calendars (EU), and settlement-driven entry calendars.
Paragraph IV risk for this class is primarily formulation and regimen mapping rather than basic composition-of-matter claims.
The residual IP landscape matters most for specific strengths, dosage forms, and labeled regimens, not for “the class” in general.

FAQs

1) Do aromatase inhibitor generics need to match specific solid-state forms to avoid infringement?

When solid-state form patents are enforceable and scope covers the polymorph/crystal form used in a generic’s manufacturing, then yes. Design-around often depends on the specific form and process controls targeted by the claim.

2) Can courts block substitution of aromatase inhibitor generics even after FDA approval?

Yes, if enforceable patents are found infringed and injunctions or settlements restrict launch or on-label use in ways tied to method-of-use or formulation claims.

3) Are pediatrics-related extensions a meaningful driver for aromatase inhibitor exclusivity?

In established APIs, pediatric-related exclusivity or added protections can contribute to longer tail protection, but in most cases the dominant remaining drivers remain secondary formulation and method-of-use patents.

4) Which matters more for ANDA challenges: bioequivalence data or patent claim scope?

Patent claim scope controls infringement and is assessed against the generic product’s formulation and manufacturing. Bioequivalence supports FDA approval, not patent non-infringement.

5) What is the most likely place for late-cycle “life-cycle” patents in L02BG?

Tablets and solid-state forms, plus regimen-based method-of-use claims tied to specific patient groups and duration windows.

References

European Medicines Agency (EMA). European patent term and SPC framework overview.
U.S. Food and Drug Administration (FDA). Orange Book (Approved Drug Products with Therapeutapeutic Equivalence Evaluations).
U.S. Code. 35 U.S.C. § 271(e) and Hatch-Waxman framework.